Longevity Patent Family

HUMAN PLURIPOTENT STEM CELL-DERIVED SENOMORPHIC EXTRACELLULAR VESICLE COMPOSITION FOR TREATING CELLULAR SENESCENCE AND STEM CELL DEGENERATION

Source-linked patent metadata for HUMAN PLURIPOTENT STEM CELL-DERIVED SENOMORPHIC EXTRACELLULAR VESICLE COMPOSITION FOR TREATING CELLULAR SENESCENCE AND STEM CELL DEGENERATION, including priority, record stage and longevity-topic connections.

Patent-family snapshot

Application publication visible

Family grouping brings related publications for the same invention together, instead of counting every national filing as a separate technology.

Representative publication
WO2026084555A1
Earliest priority
October 17, 2024
Latest publication
April 23, 2026
Family publications
1
Patent offices
1
Patent-to-Evidence Translation Map

What is happening in the same scientific field?

These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.

Senescence-associated secretory phenotype

Human evidence is visible; an active trial pathway is not yet visible

9 human-evidence records · 0 active trials · 4,097 visible funding records · 4,074 universities

Organizations

Organizations named in this family

UNIV KOREA RES & BUS FOUND [KR]Applicant
Longevity context

Topics connected by metadata

Intercellular communication88% metadata match
Knowledge connections

What this family cites

Earlier patent references
0
Scientific and other non-patent references
0
Priority dates represented
2

References show which earlier documents the patent record points to. They do not validate the invention or prove that cited research supports its claims.

Technical classification

How the patent office classifies this invention

No patent classification is available in the retained record.

Verify in the original patent source →